| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H12F4N4O2 |
| Molecular Weight | 404.3178 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)N(C1=CC=C(C(N)=O)C(=N1)C2=C(F)C=C(F)C=C2)C3=C(F)C=CC=C3F
InChI
InChIKey=FYSRKRZDBHOFAY-UHFFFAOYSA-N
InChI=1S/C19H12F4N4O2/c20-9-4-5-10(14(23)8-9)16-11(18(24)28)6-7-15(26-16)27(19(25)29)17-12(21)2-1-3-13(17)22/h1-8H,(H2,24,28)(H2,25,29)
VX-702 is a highly selective inhibitor of p38α MAPK kinase, developed by Vertex Pharmaceuticals Inc in collaboration with Kissei Pharmaceuticals Co. Ltd for potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. VX-702 was evaluated in two phase II clinical trials against rheumatoid arthritis, but its development was discontinued by Vertex.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
In the study of rheumatoid arthritis, VX-702 was administered orally in the doses of 5 and 10 mg b.i.d.
Route of Administration:
Oral
ACTIVE MOIETY
